Most cases of acute nonvariceal gastrointestinal hemorrhage resolve spontaneously and of those that do not, the majority respond to conservative medical management measures such as fluid resuscitation, correction of any coagulopathy and administration of blood products. In those cases that are refractory to medical management, endoscopy is the mainstay for diagnosis and treatment. However, there is a subset of patients in whom endoscopic management is ineffective, and imaging evaluation with an accompanying alternative intervention is necessary for bleeding control because of recurrence or massive hemorrhage. Localization and characterization of the bleeding source are important in determining the appropriate intervention, as treatment options range from minimally invasive catheter-directed therapy to extensive surgical resection. Although there has generally been a decline in the number of patients who present with acute gastrointestinal hemorrhage requiring angiography and/or transcatheter intervention, there are still patients who are unresponsive to either medical or endoscopic management and thus require emergency angiographic evaluation and possible transcatheter treatment.
The alimentary system is subdivided into the upper and lower gastrointestinal tracts and thus gastrointestinal hemorrhage is subcategorized according to the location of bleeding. The upper gastrointestinal system extends from the esophagus to the ligament of Treitz, while the latter includes the small bowel, colon and rectum. The distinction is important, as there are some characteristics that are relatively unique to each location and these may affect and determine the therapeutic approach to the particular bleeding source. Thus establishing the specific location of the bleeding as well as the etiology is critical to the treatment of patients with massive or recurrent gastrointestinal hemorrhage. Unfortunately the diagnosis can often be challenging because of the intermittent nature of gastrointestinal bleeding.
PATIENT EVALUATION AND MANAGEMENT
The initial management of a patient with acute gastrointestinal hemorrhage should be directed at stabilization through administration of fluids and blood products, correction of coagulation abnormalities, placement of appropriate intravenous access lines and insertion of a nasogastric tube if needed. The vital signs should be closely monitored for signs of active bleeding that may manifest as tachycardia, hypotension and potential hypoxemia. Although persistent melena, hematochezia or hematemesis may provide direct clinical evidence of active hemorrhage, hemodynamic instability despite vigorous resuscitation is the best indicator of active bleeding that may be angiographically demonstrable.
Acute gastrointestinal hemorrhage far more frequently involves an upper than a lower gastrointestinal source, with the former most commonly due to either peptic ulcer disease or gastritis. The most common etiology of lower gastrointestinal hemorrhage, in young adults, is inflammatory bowel disease, while in patients older than 50 years, the cause is diverticulitis (Figure 1) and to a lesser extent, angiodysplasia. The colon is the source of lower gastrointestinal hemorrhage in 80% of individuals, with the bleeding site originating in the ascending colon in one-third, the transverse colon in another one-third, and the remainder in the descending colon and rectosigmoid. A small bowel source of lower gastrointestinal hemorrhage occurs in only 20% of patients.
Figure 1 Example of a bleeding colonic diverticulum.
A: Arterial phase of a superior mesenteric artery arteriogram, obtained in a patient with acute lower gastrointestinal (GI) bleeding and a prior history of diverticulitis shows a rounded contrast collection (white arrow) arising from a branch of the right colic artery; B: In the later arterial phase the collection (white arrowhead) has increased in size but maintains the rounded configuration. The extravasated contrast medium is pooling in a colonic diverticulum, indicating that diverticular hemorrhage is the etiology of the lower GI bleeding.
If an upper gastrointestinal bleeding source seems most likely, endoscopy should be the initial diagnostic study, as the source can usually be identified and treated by the endoscopist. Unfortunately the endoscopic detection and treatment success rates in patients with lower gastrointestinal hemorrhage are generally less than with an upper source, particularly if rapid and significant bleeding is present.
ANGIOGRAPHIC EVALUATION OF ACUTE GASTROINTESTINAL HEMORRHAGE
Any angiographic evaluation of a patient with acute gastrointestinal hemorrhage should begin with the selective catheterization of the artery supplying the most likely site of bleeding, as determined by the available clinical, endoscopic and imaging data. Thus for suspected upper gastrointestinal hemorrhage, the celiac artery should first be evaluated (Figure 3), followed by the superior mesenteric artery (SMA), as the latter may contribute to a site of upper gastrointestinal hemorrhage through the pancreaticoduodenal arcade. The lower gastrointestinal tract, however, is the primary territory within the distribution of the SMA. It supplies the small bowel and the ascending and transverse portions of the colon, while the inferior mesenteric artery (IMA) supplies the splenic flexure, descending and sigmoid colonic segments as well as the rectum and anus. An additional arterial supply to the rectosigmoid and anus arises from the internal iliac arteries and this may become a dominant vascular pathway if there is IMA occlusion. The SMA becomes another collateral pathway in the presence of IMA occlusion and may provide the entire arterial supply to the descending and sigmoid colon via either the Arc or Riolan or the marginal artery of Drummond. One should be aware of the numerous mesenteric circulatory variations that may occur in the presence of occlusive disease. Furthermore, congenital variant vascular anatomy must be considered during the angiographic evaluation of gastrointestinal bleeding. For example, the entire middle colic artery may originate from the dorsal pancreatic artery in up to 2% of patients (Figure 4). If this situation exists, a celiac arteriogram may be required when investigating lower gastrointestinal bleeding, in order to fully evaluate the colonic arterial supply, particularly in the presence of negative SMA and IMA arteriograms. If SMA, IMA, celiac, and internal iliac arteriography fail to either localize active hemorrhage or to demonstrate all the mesenteric vascular segments, then variant anatomy must be considered. There are known anomalous vessels that may arise directly from the abdominal aorta, such as an anomalous ileocolic artery or a middle mesenteric artery.
Figure 3 Angiographic diagnosis and transcatheter treatment of duodenal hemorrhage.
A: Celiac digital subtraction angiography (DSA) arteriogram obtained in a patient with copious bleeding seen endoscopically in the duodenum shows focal contrast extravasation (black arrow) arising from the gastroduodenal artery (GDA); B: An image slightly later in the arterial phase of the DSA shows increasing extravasation (black arrow); C: The GDA was successfully coil embolized using microcoils (black arrowheads) through a microcatheter; D: An superior mesenteric artery DSA arteriogram was performed after the coil embolization in order to exclude any additional contribution to the duodenal hemorrhage from the pancreaticoduodenal arcade, as the duodenum has a rich collateral blood supply.
Figure 4 Inferior mesenteric artery digital subtraction angiography arteriogram shows the marginal artery of Drummond (black arrowheads), which courses along the mesenteric border of the colon.
There is retrograde filling of the left branch of the middle colic artery (black arrow), which arises from the dorsal pancreatic artery (white arrow) as an anatomic variant. There is also filling of pancreatic branches (long white arrows) along with partial opacification of the splenic and hepatic arteries.
The classic angiographic finding denoting active gastrointestinal bleeding is extravasation of contrast material (Figure 5). Extravasation signifies a breach in the integrity of the arterial wall that permits the angiographic contrast to freely exit from the vessel. Extravasated contrast, therefore, does not have the typical tubular appearance of a vascular structure but instead distributes irregularly and often without a pattern. It may sometimes pool within the gastric rugae or within bowel folds or haustra so that the contrast assumes the appearance of a vein, the “pseudo-vein sign” (Figure 6). This may be differentiated from a true venous structure by the unusual location and appearance, as well as by the persistence beyond the venous phase of the contrast injection. Extravasation must also be differentiated from entities that mimic its appearance, such as a hypervascular bowel mucosa, adrenal gland vascular blush and DSA misregistration artifacts from bowel peristalsis or respiratory motion. There are also angiographic findings other than contrast extravasation that may be seen in certain pathologic conditions and are suggestive of the cause and/or source of the gastrointestinal bleeding. In peptic ulcer disease, for example, small contrast collections may be seen within an ulcer crater, or may outline the gastric or duodenal mucosa. The angiographic demonstration of a gastric ulcer usually requires subselective catheterization of celiac arterial branches such as the left gastric artery, although the bleeding source may also potentially arise from the right gastric artery, the short gastric artery, or either the left or right gastroepiploic arteries. Additionally, the gastroduodenal artery may supply a bleeding pyloric or duodenal ulcer.
Figure 5 Contrast extravasation demonstrating location of lower gastrointestinal bleeding.
A: Superior mesenteric artery arteriogram shows an amorphous contrast collection (black arrow) arising from the left branch (long black arrow) of the middle colic artery; B: Later in the arterial phase the collection has increased and is layering dependently in the colon, assuming the configuration of the haustra. This extravasated contrast medium denotes the site of lower gastrointestinal bleeding.
Figure 6 The pseudovein sign in gastrointestinal hemorrhage.
A: Superior mesenteric artery arteriogram shows a branching contrast collection (black arrows), overlying the gastric air shadow. The collection has the appearance of a vascular structure such as a vein; B: A later image in the arterial injection shows that the collection (black arrowhead) has a more amorphous appearance, and represents extravasation. The former appearance is an example of the “pseudovein sign”.
Arterial pseudoaneurysm is another angiographic abnormality that may be identified as a source of gastrointestional hemorrhage. These occur most frequently in patients who have chronic pancreatitis. Hemosuccus pancreaticus refers to bleeding through the pancreatic duct, and may be caused by an arterial pseudoaneurysm that has resulted from chronic exposure of the arterial wall to the inflammatory effects of the pancreatic digestive enzymes. The weakened arterial wall may permit the intermittent bleeding that characterizes hemosuccus pancreaticus, or the pseudoaneurysm may catastrophically rupture and cause acute massive, life-threatening intra-abdominal hemorrhage. Contrast enhanced computed tomographic angiography can be very effective in demonstrating these characteristic pseudoaneurysms (Figure 7) and thus has an increasingly important role in the diagnosis of acute gastrointestinal hemorrhage that is secondary to pancreatitis, while angiographic transcatheter therapy provides the best treatment option in these patients (Figures 8 and 9).
Figure 7 Upper gastrointestinal hemorrhage from pancreatitis related pseudoaneurysm.
A: Axial contrast-enhanced computed tomography (CECT) scan, obtained in a patient who presented with hematemesis, shows pancreatic calcifications (long black arrows) indicating chronic pancreatitis and an enhancing mass (black arrows) in the pancreatic tail; B: Coronal CECT shows the rounded enhancing mass (black arrow) with surrounding inflammatory changes. This is suspicious for a pancreatitis-related pseudoaneurysm as the source of the upper gastrointestinal hemorrhage.
Figure 8 Transcatheter treatment of a pancreatitis related pseudoaneurysm.
A: Selective splenic artery digital subtraction angiography arteriogram shows that the pseudoaneurysm (white arrow) arises directly from the splenic artery; B: Coil embolization of the pseudoaneurysm (black arrow) and of the splenic artery (black arrowheads) both proximal and distal to the pseudoaneurysm was successful in controlling the hemorrhage. Arterial pseudoaneurysms associated with pancreatitis have a significant risk of rupture; if this occurs there is an extremely high mortality rate.
Figure 9 Treatment of ruptured pseudoaneurysm with covered intravascular stent.
A: Digital subtraction angiography arteriogram obtained in a patient with upper gastrointestinal bleeding and a history of pancreatitis shows irregular dilatation of the proximal superior mesenteric artery (black arrows) and contrast extravasation (black arrowhead) consistent with pseudoaneurysm rupture; B: The hemorrhage was successfully controlled with covered stent (white arrows) placement.
Given both the diffuse nature of the inflammatory process seen in pancreatitis, and the pancreatic arterial supply from both the celiac artery and SMA, pseudoaneurysms may be present involving either or both of these arteries or their branches. The angiographic evaluation must thus include both the celiac and SMA and transcatheter treatment may involve multiple sites. Surgical intervention is very difficult in these patients because of the extensive inflammatory process that characterizes this cause of bleeding (Figure 10).
Figure 10 Life-threatening hemorrhage from pancreatitis related pseudoaneurysm.
A: Celiac digital subtraction angiography arteriogram obtained in a patient with intermittent upper gastrointestinal bleeding and a history of chronic pancreatitis shows an irregular caliber to the splenic artery (black arrows) and a small pseudoaneurysm (white arrow). No intervention was performed at the time of this examination; B: Two weeks after the celiac arteriogram the patient presented with acute onset of severe abdominal pain and profound hypotension. Repeat angiography showed brisk contrast extravasation (black arrows) from the splenic artery. Note the marked vasoconstriction (white arrows) of the hepatic and splenic arteries due to the life-threatening hemorrhage.
Arterial pseudoaneurysms may also be seen in patients with chronic occlusive disease of the celiac artery, and involve the pancreaticoduodenal arteries (Figure 11). These pseudoaneurysms are rupture-prone and may cause massive acute upper gastrointestinal hemorrhage. Because of the occlusion of the origin of the celiac artery, the angiographic evaluation involves the selective catheterization of the SMA, in order to image the pancreaticoduodenal arcade. Any intervention, such as coil embolization, must typically also be performed via an SMA access, although there are cases in which a percutaneous route has been used to treat such an abnormality.
Figure 11 Digital subtraction angiography obtained with the catheter tip (long black arrow) in the superior mesenteric artery shows tortuous and dilated inferior pancreaticoduodenal arteries with at least two small pseudoaneurysms (black arrows).
There is retrograde filling of the celiac arterial branches via the inferior pancreaticoduodenal arteries arcade, because the celiac origin is occluded (white arrow). The pseudoaneurysms are at risk of rupture.
Angiodysplasia and arteriovenous malformations (AVMs) of the bowel are characterized by the early and prolonged opacification of a draining vein, accompanied by an abnormal tangle of vessels that may appear as a blush (Figure 12). The simultaneous filling of the feeding artery and the draining vein may give a characteristic “tram-track” sign. Although up to 80% of angiodysplastic lesions are in the right colon, other parts of the gut, particularly the lower small intestine, may be affected. Angiodysplasia is relatively common in older patients, aged 60 to 80 years, and may be an asymptomatic incidentally noted lesion identified at colonoscopy. Because the dilated vessels are superficial, however, they may bleed spontaneously and patients can either present acutely with overt hemorrhage or insidiously with iron deficiency anemia. Once bleeding has begun, recurrent episodic hemorrhage or persistent iron deficiency anemia requiring repeated transfusion is not uncommon. Symptomatic lesions may be effectively treated endoscopically with laser or heat coagulation or with sclerotherapy. These procedures are not risk-free in the thin cecal wall and have been known to cause serosal irritation and post-treatment bleeding. For patients with repeated bleeding from intestinal vascular malformations, pharmacological treatment using estrogens (e.g., 0.05 mg ethinyl estradiol and 1 mg norethisterone) can be effective in reducing transfusion requirements. Although transcatheter arterial embolization of colonic angiodysplasia can be an effective treatment in emergencies[8-11], it carries a significant risk of inducing colonic ischemia. Definitive and curative treatment usually requires surgical resection.
Figure 12 Magnified view from a superior mesenteric artery arteriogram shows an area of abnormal vascularity (white arrowhead) in the cecal area, with an early draining vein (long white arrow) paralleling the arterial inflow (white arrow).
This simultaneous filling of the feeding artery and draining vein is known as the “tram-track” sign and is characteristic of angiodysplasia.
ANGIOGRAPHIC MANAGEMENT OF ACUTE GASTROINTESTINAL HEMORRHAGE
Transcatheter arterial embolization
Transcatheter arterial embolization is an effective means of interrupting blood flow to the bleeding source, while maintaining bowel viability. Although there is a risk of bowel ischemia and/or infarction, the coaxial catheter systems and the variety of available embolic agents that are now used for embolotherapy allow for very selective and precise treatment, and thus have decreased the incidence of these complications. Additionally, the gastrointestinal tract has a rich collateral blood supply, with extensive vascular arcades that permit safe embolization if certain principles are observed. The objective of embolization therapy is to achieve a compromise between selective arterial inflow reduction and maintenance of collateral arterial blood flow. Arterial inflow must be sufficiently decreased to allow for hemostasis, but not to an extent that causes complete devascularization. Achieving a superselective embolization in the presence of an intact coagulation cascade is key to attaining a successful outcome using this form of treatment.
In most of the early literature, embolization was performed proximally in the visceral arteries because microcatheters facilitating superselective embolization were not yet available. The technique that is currently used for transcatheter arterial embolization involves the initial placement of a larger caliber diagnostic catheter (4 or 5 Fr) into the main trunk of the feeding artery, followed by coaxial introduction of a microcatheter. The latter is the crucial step in modern embolization and requires the superselective catheterization of the target artery using a 3-Fr coaxial microcatheter over a 0.018 inch or 0.014 inch guidewire. The guidewire tip must be carefully advanced under fluoroscopic monitoring in a smooth and controlled fashion in order to avoid vasospasm, dissection, or vessel perforation. Vasodilators such as verapamil (100-200 μg) or nitroglycerin (100-300 μg) may be used to treat any vasospasm that may be induced by guidewire and/or microcatheter passage. Using the wire as a guide, the catheter should travel closely behind and eventually engage the target vessel.
The optimal level of embolization varies according to the bleeding site. In general, embolization should not be routinely attempted unless a microcatheter has been advanced close to the bleeding point so that the embolic agent can be deployed as selectively as possible. The risk of infarction is related to both the embolic agent and the proximity of embolization. In the colon, for example, ischemia and infarction may result from embolization of proximal branches supplying a large area of bowel or embolization of multiple distal arteries that do not have sufficient collateral flow. Submucosal collateral blood flow may be preserved only when arteries to a short segment of bowel are embolized, so one should attempt to occlude arteries to as limited a segment of bowel as possible. One must be aware that embolization in the setting of prior gastrointestinal surgery or radiation therapy may impose a greater risk of infarction because of the associated interruption of collaterals.
Various agents may be used for transcatheter embolization. The most commonly used agents include pledgets of absorbable gelatin sponge (Gelfoam®, Pfizer, Inc., NY, United States), particulate agents such as polyvinyl alcohol (e.g., Bead BlockTM, Biocompatibles International, Farnham, United Kingdom) and other spherical agents (e.g., Embospheres® BioSphere Medical, Inc., Rockland, MA, United States; EmbozeneTM microspheres CeloNova BioSciences, Inc., Newnan, GA, United States) and microcoils of various sizes and configurations. Microcoils have the advantage of good radiopacity that allows for a precise deployment permitting reduction of the arterial perfusion pressure to the bleeding site while preserving sufficient collateral flow. The wide range of coil sizes allows one to appropriately match the coil to the target vessel diameter. Each microcoil is delivered sequentially, until hemostasis has been achieved. Intra-arterial microcoil placement is analogous to placement of a surgical ligature. The coil physically occludes the vascular lumen and causes a decreased perfusion pressure, while the attached synthetic fibers maximize thrombogenicity.
Gelfoam pledgets and particulate agents may also be used successfully, but are more difficult to control than microcoils. Gelfoam is a temporary agent and often cannot easily be deployed superselectively. A disadvantage of the particulate agents is that small diameters may reach the intramural circulation distal to the collaterals, thereby risking bowel infarction, or may reflux into non-target arteries.
The liquid embolic agents n-butyl cyanoacrylate, known by the proprietary name Trufill® (Cordis Neurovascular, Miami Lakes, FL, United States), and liquid polyvinyl alcohol copolymer (Onyx®, ev3 Neurovascular, Irvine, CA, United States) have also been used successfully in treating gastrointestinal hemorrhage[13,14]. An advantage of liquid agents is that they may be used effectively in very small caliber vessels. However, the operator must be very familiar with the use of these agents, in order to achieve optimal outcomes and minimize complications.
Technical challenges of transcatheter arterial embolization
Because of the intermittent nature of gastrointestinal hemorrhage, arteriography fails to demonstrate a distinct bleeding site in a considerable number of patients, and thus embolization is not possible. Furthermore, a negative arteriogram fails to guide emergency surgery and delays operative decision-making. In such circumstances, some investigators have advocated provocation of bleeding with vasodilators, anticoagulants, and/or thrombolytics in association with tagged red blood cell scans or angiography[15,16]. This may be appropriate for a patient who has undergone multiple blood transfusions and a prior exhaustive work-up that has failed to localize the occult bleeding site. Additionally there must be no contraindications to the administration of a thrombolytic agent. If provocative angiography is undertaken, one should arrange for surgical backup in the event that uncontrollable bleeding occurs.
Different methods of inducing bleeding and different rates of success have been reported. An optimal protocol has yet to be established and the procedure has also yet to become accepted by clinicians as part of the evaluation of gastrointestinal bleeding. The technique continues to evolve as experience and comfort with the use of thrombolytic agents in the setting of nonlocalized bleeding increases. One reported protocol used a combination of intravenous heparin, intra-arterial tolazoline, and intra-arterial tissue-type plasminogen activator (t-PA) to provoke bleeding. Doses used included 3000-10 000 U heparin, 25-100 mg intra-arterial tolazoline, and 10-50 mg intra-arterial t-PA (mean, 20.3 mg). The investigators also noted that more patients had bleeding provoked after smaller rather than larger doses of t-PA. Tolazoline (Priscoline) was formerly used for a vasodilatory effect, but was withdrawn from the United States market in 2002 by Novartis Pharmaceuticals, the sole manufacturer of this drug. Alternative intra-arterial vasodilators that may be used include verapamil (100-200 μg) and nitroglycerin (100-300 μg), with the former showing the greater vasodilatory effects. In the authors’ practice, we have occasionally used a similar transcatheter regimen, in which a vasodilator and a dose of 5000 U intra-arterial heparin and 5-10 mg intra-arterial t-PA were administered, with resultant provocation of bleeding that allowed for subsequent successful transcatheter embolization.
Superselective embolization of the arterial supply to the bleeding source may be technically demanding, particularly in older patients who may have significant atherosclerotic disease. The mesenteric vasculature and the various arterial arcades are often tortuous, and the smaller arteries are prone to vasospasm and care must be taken to avoid dissection.
An arterial bleeding site may receive a dual blood supply as a result of the rich collateral arcades that characterize the mesenteric circulation. One must therefore catheterize and inject both potential sources of perfusion to the lesion and be prepared to embolize two separate vessels if necessary. Although this dual approach will control the hemorrhage, it will also increase the risk of bowel ischemia.
While angiodysplasia and AVMs may initially respond to embolization, recurrent hemorrhage is frequent and, as noted, surgical resection of the involved bowel segment is often required. A small bowel AVM is much more easily localized at surgery if an embolization coil has been placed distally in the arterial branch that supplies the lesion, so that it is palpable or visible to the surgeon.
Results of transcatheter arterial embolization
The current technique of embolization in the treatment of acute gastrointestinal hemorrhage successfully controls bleeding in about 80%-90% of patients[19-23]. Recurrent hemorrhage is infrequent, with the exception of angiodysplasia, AVMs and inflammatory lesions. Recurrences can usually be angiographically re-evaluated and, if a bleeding source is identified, treated with repeat embolization.
Complications of transcatheter arterial embolization
Transcatheter arterial embolization for the treatment of acute gastrointestinal hemorrhage is safe, with major adverse events occurring in less than 2% of patients. A fraction of patients embolized superselectively will develop minor, asymptomatic and self-limited ischemic changes such as small ulcers that can only be detected incidentally via objective follow-up methods such as endoscopy, pathologic surgical specimen or by a radiographic imaging examination. Additionally, superselective microcoil embolization is unlikely to result in delayed infarction. If major bowel ischemia occurs several months to years later, it is more likely to be attributable to a new and acute insult such as thromboembolic disease affecting the mesenteric arterial bed.
Non-target embolization with microcoils is rare, as the coils are introduced only after a microcatheter has been successfully negotiated into the target vessel. One must carefully choose appropriate sized microcoils however, as a coil that is oversized relative to the target vessel may displace the microcatheter from its superselective position. This could lead to deployment of the microcoil in a non-target location (Figure 13). Similarly, undersized coils may fail to adequately occlude the target vessel or may lodge distal to the lesion that is to be treated.
Figure 13 Example of nontarget embolization during treatment of lower gastrointestinal bleeding.
A: Superior mesenteric artery arteriogram obtained in a patient with lower gastrointestinal bleeding shows a focal contrast collection (black arrow) arising from a branch of the ileocolic artery; B: A microcatheter was introduced and was subselectively positioned with the tip (long black arrow) immediately proximal to the focal extravasation and a microcoil (black arrow) was placed; C: While attempting to place a second microcoil, the microcatheter tip was displaced proximally resulting in coil placement in a nontarget location (black arrowhead). Repeat digital subtraction angiography shows that the second coil is nonocclusive and the initially placed coil has successfully controlled the bleeding source.
Vasopressin infusion therapy
Vasopressin (Pitressin) is a naturally occurring hormone that causes constriction of both the mesenteric arteries and of the smooth muscle of the bowel wall. The intra-arterial transcatheter infusion of vasopressin proximal to a mesenteric arterial bleeding site will reduce blood flow, thereby lowering the perfusion pressure and permitting clot formation at the lesion (Figure 14). There are several situations in which this form of treatment for gastrointestinal bleeding should not be used. These include bleeding that originates from a large diameter artery such as the gastroduodenal, splenic or proximal SMA or which occurs at a site with a dual blood supply such as the duodenum. It is also contraindicated in patients who have severe coronary artery disease, extreme hypertension, limb ischemia or cardiac arrhythmias. Superselective embolotherapy is now used preferentially over vasopressin infusion for treating gastrointestinal hemorrhage because embolization poses fewer risks and can be completed more rapidly than a vasopressin infusion protocol. Vasopressin may still be useful in certain situations, despite the numerous side effects and the high re-bleeding rates. One may consider using vasopressin for treating lesions that are inaccessible to a microcatheter, for diffuse mucosal oozing, and for controlling multiple sites of hemorrhage in high-risk surgical patients.
Figure 14 Vasopressin infusion therapy for lower gastrointestinal hemorrhage.
A: Inferior mesenteric digital subtraction angiography arteriogram shows contrast extravasation (black arrow) in the rectosigmoid colon, arising from a branch of the superior hemorrhoidal artery (white arrow); B: Following transcatheter arterial vasopressin infusion, there is no longer any evidence of active bleeding from the superior hemorrhoidal (white arrow) arterial distribution.
Technique of vasopressin infusion therapy
Vasopressin is typically infused into the central vessel (e.g., celiac artery, SMA or IMA) that supplies the bleeding site via a catheter that has been placed proximally; to avoid bowel ischemia and potential infarction, a distal infusion should not be attempted. Vasopressin (100 U) is mixed in 500 mL of normal saline and the infusion is started at 0.2 U/min for 20 min using an arterial infusion pump set at 60 mL/min. If there is no cessation of bleeding, the dose is increased by 0.1 U/min up to a maximum of 0.4 U/min; each dosage change is followed by a repeat angiogram 20 to 30 min later to assess the effectiveness. If the bleeding stops, the catheter is left in place for a 24-h infusion at the effective dosage, with monitoring in the intensive care unit. After another repeat angiogram shows control of bleeding, the vasopressin infusion is gradually reduced over 24 to 48 h and then vasopressin is replaced with an infusion of normal saline or 5% dextrose in water for 6-12 h.
Results of vasopressin infusion therapy
This form of therapy is particularly effective in controlling diverticular and gastric mucosal hemorrhage, with initial success rates ranging from 60%-90%[24-27]. As previously noted, however, there is a very high rate of re-bleeding that may be up to 50%.
Complications of vasopressin infusion therapy
Mild abdominal pain may occur at the initiation of the infusion and should be closely monitored, as persistence and/or worsening can be an indicator of bowel ischemia. If side effects develop during treatment, the vasopressin can be tapered to a lower dose or may need to be discontinued. Additional side effects and potential complications of vasopressin therapy include angina, myocardial infarction, hypertension, volume overload, abdominal cramps, and mesenteric ischemia. Some of the potential adverse effects may be treated or even pretreated. The simultaneous administration of intravenous, sublingual or transdermal nitroglycerin may prevent or reverse the cardiotoxic side effects of vasopressin infusion.